Heron Therapeutics (HRTX) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intercure (INCR) has outperformed Heron Therapeutics (HRTX) over the past year, losing 37.5% versus a loss of 73.5%. Over five years, INCR leads with a -85.8% price change compared with -96.6% for HRTX. Intercure is the larger company by market cap ($75.5 million vs $68.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | INCR |
|---|---|---|
| Share price | $0.3582 | $5.03 |
| Market cap | $68.01M | $75.47M |
| 1-day change | -6.79% | -1.95% |
| YTD return | -72.45% | +10.55% |
| 1-year return | -73.47% | -37.52% |
| 5-year return | -96.62% | -85.81% |
| EPS (TTM) | $-0.18 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $8.40 |
| 52-week low | $0.26 | $3.40 |
| Distance from 52-week high | -77.33% | -40.12% |
| Analyst consensus | none | — |
| Avg. price target upside | +1854.22% | — |
| Average volume | 2.59M | 21.73K |
| Shares outstanding | 189.85M | 15.00M |
| Employees | 128 | 285 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed HRTX by 36.0 percentage points over the past year.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Healthcare · Biotechnology · 128 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Healthcare · Drug Manufacturers - Specialty & Generic · 285 employees
HRTX vs INCR FAQ
Which is bigger, Heron Therapeutics or Intercure?
Intercure (INCR) is larger, with a market capitalization of $75.47M compared with $68.01M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, HRTX or INCR?
INCR returned -37.52% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Intercure in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Heron Therapeutics and Drug Manufacturers - Specialty & Generic for Intercure.